DexCom
DXCM
290 hedge funds and large institutions have $8.86B invested in DexCom in 2018 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 99 increasing their positions, 100 reducing their positions, and 33 closing their positions.
52% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 33
24% more call options, than puts
Call options by funds: $30.5M | Put options by funds: $24.6M
15% more capital invested
Capital invested by funds: $7.67B → $8.86B (+$1.18B)
5% more funds holding
Funds holding: 276 → 290 (+14)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
1% less repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 100
52.29% less ownership
Funds ownership: 475.67% → 423.38% (-52%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$59.8M |
| 2 |
Millennium Management
New York
|
+$59.1M |
| 3 |
HM
HealthCor Management
New York
|
+$52.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$41.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$40.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$284M |
| 2 |
Janus Henderson Group
London,
|
-$210M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$209M |
| 4 |
Goldman Sachs
New York
|
-$76.1M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$63M |
DXCM Hedge Fund Activity: Q2 2018 in Review
290 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q2 2018, worth a combined $8.86B — up 15% from $7.67B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new DXCM positions and 33 closed out — a net gain of 17 holders — while 99 added to existing stakes and 100 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $59.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $284M.
- 290 institutional investors held DexCom (DXCM) as of Q2 2018, up from 276 in Q1 2018.
- Funds reported $8.86B of DexCom stock for Q2 2018, up 15% quarter-over-quarter.
- 50 funds opened new DexCom positions in Q2 2018 and 33 closed out, a net change of +17 holders.
- The largest DexCom buyer in Q2 2018 was Morgan Stanley, an estimated $59.8M added.
- The largest DexCom seller in Q2 2018 was T. Rowe Price Associates, an estimated $284M sold.
Based on aggregated 13F filings for Q2 2018.